MX2023000403A - Coagonistas de los receptores del peptido 1 similar al glucagon (glp-1) y del peptido insulinotropico dependiente de glucosa (gip). - Google Patents
Coagonistas de los receptores del peptido 1 similar al glucagon (glp-1) y del peptido insulinotropico dependiente de glucosa (gip).Info
- Publication number
- MX2023000403A MX2023000403A MX2023000403A MX2023000403A MX2023000403A MX 2023000403 A MX2023000403 A MX 2023000403A MX 2023000403 A MX2023000403 A MX 2023000403A MX 2023000403 A MX2023000403 A MX 2023000403A MX 2023000403 A MX2023000403 A MX 2023000403A
- Authority
- MX
- Mexico
- Prior art keywords
- peptide
- coagonists
- gip
- receptors
- glp
- Prior art date
Links
- 108010004460 Gastric Inhibitory Polypeptide Proteins 0.000 title 2
- GCYXWQUSHADNBF-AAEALURTSA-N preproglucagon 78-108 Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(N)=O)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CC=1N=CNC=1)[C@@H](C)O)[C@@H](C)O)C(C)C)C1=CC=CC=C1 GCYXWQUSHADNBF-AAEALURTSA-N 0.000 title 1
- 101001015516 Homo sapiens Glucagon-like peptide 1 receptor Proteins 0.000 abstract 1
- 208000008589 Obesity Diseases 0.000 abstract 1
- 206010012601 diabetes mellitus Diseases 0.000 abstract 1
- 108010036598 gastric inhibitory polypeptide receptor Proteins 0.000 abstract 1
- 208000019423 liver disease Diseases 0.000 abstract 1
- 235000020824 obesity Nutrition 0.000 abstract 1
- 230000002265 prevention Effects 0.000 abstract 1
- 108090000765 processed proteins & peptides Proteins 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/26—Glucagons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
- C07K14/605—Glucagons
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Organic Chemistry (AREA)
- Diabetes (AREA)
- Endocrinology (AREA)
- Gastroenterology & Hepatology (AREA)
- Epidemiology (AREA)
- Zoology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Molecular Biology (AREA)
- Immunology (AREA)
- Child & Adolescent Psychology (AREA)
- Emergency Medicine (AREA)
- Toxicology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
Se describen coagonistas peptídicos de los receptores de GLP-1 y GIP humanos, los derivados de acción prolongada de los mismos y sus usos médicos en el tratamiento y/o la prevención de la obesidad, la diabetes y/o enfermedades hepáticas.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063055063P | 2020-07-22 | 2020-07-22 | |
| EP20192415 | 2020-08-24 | ||
| PCT/EP2021/070483 WO2022018185A1 (en) | 2020-07-22 | 2021-07-22 | Glp-1 and gip receptor co-agonists |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2023000403A true MX2023000403A (es) | 2023-02-02 |
Family
ID=77179984
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2023000403A MX2023000403A (es) | 2020-07-22 | 2021-07-22 | Coagonistas de los receptores del peptido 1 similar al glucagon (glp-1) y del peptido insulinotropico dependiente de glucosa (gip). |
Country Status (15)
| Country | Link |
|---|---|
| US (1) | US20230346961A1 (es) |
| EP (1) | EP4185606A1 (es) |
| JP (1) | JP2023534130A (es) |
| KR (1) | KR20230042019A (es) |
| CN (1) | CN116157414A (es) |
| AU (1) | AU2021313377A1 (es) |
| BR (1) | BR112023000229A2 (es) |
| CA (1) | CA3184723A1 (es) |
| CL (1) | CL2023000090A1 (es) |
| CO (1) | CO2023000125A2 (es) |
| IL (1) | IL299707A (es) |
| MX (1) | MX2023000403A (es) |
| PE (1) | PE20231842A1 (es) |
| TW (1) | TW202214679A (es) |
| WO (1) | WO2022018185A1 (es) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2023305663A1 (en) * | 2022-07-13 | 2025-02-20 | Hangzhou Zhongmeihuadong Pharmaceutical Co., Ltd. | Glp-1/gip dual agonist, and preparation method therefor and use thereof |
| WO2024165571A2 (en) | 2023-02-06 | 2024-08-15 | E-Therapeutics Plc | Inhibitors of expression and/or function |
| WO2025108381A1 (zh) * | 2023-11-22 | 2025-05-30 | 杭州中美华东制药有限公司 | Glp-1r/gipr双靶点激动剂在制备动物药中的用途 |
| WO2025125576A2 (en) | 2023-12-15 | 2025-06-19 | E-Therapeutics Plc | Inhibitors of expression and/or function |
| WO2025133348A1 (en) | 2023-12-22 | 2025-06-26 | E-Therapeutics Plc | Inhibitors of expression and/or function |
| EP4686757A1 (en) | 2024-07-31 | 2026-02-04 | e-therapeutics PLC | Inhibitors of expression and/or function |
| TW202535911A (zh) * | 2024-01-12 | 2025-09-16 | 大陸商杭州中美華東製藥有限公司 | 長效glp-1/gip雙激動劑的藥物組合物 |
| WO2025196502A1 (en) | 2024-03-20 | 2025-09-25 | North Carolina Agricultural & Technical State University | Choline kinase inhibitors as a therapeutic treatment for obesity |
| WO2025264785A1 (en) * | 2024-06-21 | 2025-12-26 | Neurocrine Biosciences, Inc. | Chemically modified peptides and use thereof |
| WO2025264776A1 (en) * | 2024-06-21 | 2025-12-26 | Neurocrine Biosciences, Inc. | Chemically modified peptides and use thereof |
| WO2025264809A1 (en) * | 2024-06-21 | 2025-12-26 | Neurocrine Biosciences, Inc. | Chemically modified peptides and use thereof |
Family Cites Families (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TWI362392B (en) | 2005-03-18 | 2012-04-21 | Novo Nordisk As | Acylated glp-1 compounds |
| CL2009001425A1 (es) | 2008-06-17 | 2010-04-30 | Univ Indiana Res & Tech Corp | Analogos de glucagon con un aminoacido aromatico grande que carece de cadena lateral de imidazol que le confiere actividad agonista del receptor gip; composiciones farmaceutica; kit que los contiene y uso para reducir el aumento de peso, tratar la diabetes o inducir paralisis del tracto intestinal. |
| US8551946B2 (en) * | 2010-01-27 | 2013-10-08 | Indiana University Research And Technology Corporation | Glucagon antagonist-GIP agonist conjugates and compositions for the treatment of metabolic disorders and obesity |
| CA2822617A1 (en) * | 2010-12-22 | 2012-06-28 | Marcadia Biotech, Inc. | Methods for treating metabolic disorders and obesity with gip and glp-1 receptor-active glucagon-based peptides |
| KR102002783B1 (ko) | 2011-06-10 | 2019-07-24 | 베이징 한미 파마슈티컬 컴퍼니 리미티드 | 포도당 의존성 인슐리노트로핀 폴리펩타이드 유사물질, 이의 약학적 조성물 및 응용 |
| EP4331667A3 (en) * | 2012-03-22 | 2024-05-08 | Novo Nordisk A/S | Compositions comprising a delivery agent and preparation thereof |
| EA028665B1 (ru) | 2012-05-03 | 2017-12-29 | Зилэнд Фарма А/С | Соединения - двойные агонисты gip-glp-1 и способы |
| CA2894765A1 (en) | 2012-12-21 | 2014-06-26 | Sanofi | Exendin-4 derivatives as dual glp1/gip or trigonal glp1/gip/glucagon agonists |
| AU2014261336B2 (en) * | 2013-05-02 | 2019-02-28 | Novo Nordisk A/S | Oral dosing of GLP-1 compounds |
| MA38472B1 (fr) | 2013-05-28 | 2018-09-28 | Takeda Pharmaceuticals Co | Composé peptidique |
| HK1226084A1 (zh) | 2013-08-16 | 2017-09-22 | Medimmune Limited | 用於治疗糖尿病的gip和glp-1受体双重激动剂 |
| US10093713B2 (en) * | 2013-11-06 | 2018-10-09 | Zealand Pharma A/S | GIP-GLP-1 dual agonist compounds and methods |
| EP3080154B1 (en) | 2013-12-13 | 2018-02-07 | Sanofi | Dual glp-1/gip receptor agonists |
| WO2015086728A1 (en) | 2013-12-13 | 2015-06-18 | Sanofi | Exendin-4 peptide analogues as dual glp-1/gip receptor agonists |
| US10232020B2 (en) * | 2014-09-24 | 2019-03-19 | Indiana University Research And Technology Corporation | Incretin-insulin conjugates |
| JOP20200119A1 (ar) * | 2015-01-09 | 2017-06-16 | Lilly Co Eli | مركبات مساعد مشترك من gip وglp-1 |
| KR20210031533A (ko) | 2018-07-23 | 2021-03-19 | 일라이 릴리 앤드 캄파니 | Gip/glp1 공효능제 화합물 |
-
2021
- 2021-07-22 CA CA3184723A patent/CA3184723A1/en active Pending
- 2021-07-22 PE PE2023000027A patent/PE20231842A1/es unknown
- 2021-07-22 JP JP2022577749A patent/JP2023534130A/ja active Pending
- 2021-07-22 BR BR112023000229A patent/BR112023000229A2/pt unknown
- 2021-07-22 CN CN202180060412.2A patent/CN116157414A/zh active Pending
- 2021-07-22 WO PCT/EP2021/070483 patent/WO2022018185A1/en not_active Ceased
- 2021-07-22 MX MX2023000403A patent/MX2023000403A/es unknown
- 2021-07-22 AU AU2021313377A patent/AU2021313377A1/en active Pending
- 2021-07-22 US US18/016,947 patent/US20230346961A1/en active Pending
- 2021-07-22 TW TW110126884A patent/TW202214679A/zh unknown
- 2021-07-22 IL IL299707A patent/IL299707A/en unknown
- 2021-07-22 EP EP21749557.1A patent/EP4185606A1/en not_active Withdrawn
- 2021-07-22 KR KR1020237002583A patent/KR20230042019A/ko active Pending
-
2023
- 2023-01-06 CO CONC2023/0000125A patent/CO2023000125A2/es unknown
- 2023-01-09 CL CL2023000090A patent/CL2023000090A1/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| IL299707A (en) | 2023-03-01 |
| AU2021313377A1 (en) | 2023-02-02 |
| CN116157414A (zh) | 2023-05-23 |
| US20230346961A1 (en) | 2023-11-02 |
| WO2022018185A1 (en) | 2022-01-27 |
| KR20230042019A (ko) | 2023-03-27 |
| CA3184723A1 (en) | 2022-01-27 |
| CO2023000125A2 (es) | 2023-04-17 |
| EP4185606A1 (en) | 2023-05-31 |
| PE20231842A1 (es) | 2023-11-21 |
| CL2023000090A1 (es) | 2023-07-07 |
| JP2023534130A (ja) | 2023-08-08 |
| TW202214679A (zh) | 2022-04-16 |
| BR112023000229A2 (pt) | 2023-01-31 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2023000403A (es) | Coagonistas de los receptores del peptido 1 similar al glucagon (glp-1) y del peptido insulinotropico dependiente de glucosa (gip). | |
| MX2023000303A (es) | Coagonistas de los receptores del peptido 1 similar al glucagon (glp-1) y del polipeptido insulinotropico dependiente de glucosa (gip) adecuados para el suministro oral. | |
| ECSP21004913A (es) | Compuestos coagonistas de gip/glp1 | |
| PE20221518A1 (es) | Analogos de incretina y sus usos | |
| BR112021020071A2 (pt) | Compostos agonistas duplos do receptor de glp-1 e gip e uso dos mesmos | |
| AR121093A1 (es) | Compuestos coagonistas de gip / glp1 | |
| HRP20220995T1 (hr) | Trostruki aktivator koji aktivira glukagonski, glp-1 i gip receptore | |
| AR084558A1 (es) | Metodos para tratar trastornos metabolicos y obesidad con peptidos basados en glucagon activos para el receptor de peptido insulinotropico dependiente de glucosa (gip)/peptido-1 similar al glucagon (glp-1) | |
| ECSP22008098A (es) | Compuestos agonistas de gipr | |
| CO2019014028A2 (es) | Posologías para la administración de análogos de péptido de tipo glucagon-2 (glp-2) | |
| CY1122028T1 (el) | Gip και glp-1 συν-αγωνιστικές ενώσεις | |
| PE20211417A1 (es) | Analogos novedosos de glp-1 | |
| AR061203A1 (es) | Moduladores del receptor glp-1 modificados en la terminal n | |
| HN2003000217A (es) | Agonistas del receptor (vpac2) del peptido activamente de la adenilato ciclasa hipofisiaria (pacap) y sus metodos de uso farmacologico. | |
| PE20251259A1 (es) | Agonista dual de glp-1/gip, metodo de preparacion y uso del mismo | |
| ZA202310867B (en) | Multi-agonist and use thereof | |
| CL2017002293A1 (es) | Tratamiento de pacientes con diabetes mellitus de tipo 2 | |
| MX2023009550A (es) | Antagonistas del receptor del peptido-1 tipo glucagon. | |
| AR123039A1 (es) | Coagonistas de los receptores de glp-1 y gip | |
| MX2022006743A (es) | Formulaciones liquidas estables de peptido 1 similar al glucagon o analogos del mismo. | |
| DOP2004000932A (es) | Proteinas de fusion de analogos del glp-1 |